In this video interview, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, makes the case ...
Veristat’s acquisition adds substantial regulatory and medical writing scale, strengthening integrated submission strategy ...
Partner at Global Life Sciences Alliance (GLSA) and brings over 30 years of experience in the life sciences and clinical research industry. He has worked extens ...
Partner at Global Life Sciences Alliance (GLSA), where she works across sponsors, CROs, and research sites to support study feasibility, site selection, and c ...
The FDA has granted accelerated approval to lunsotogene parvec-cwha (Otarmeni), an adeno-associated virus (AAV) vector–based ...
In today's ACT Brief, we explore organizational factors behind CRL decisions, methodological concerns with pooling amyloid ...
In this video interview, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, discusses how ...
Oral semaglutide lowered HbA1c vs placebo in a phase 3 trial in adolescents with type 2 diabetes, pending full data and ...
A newly published Cochrane systematic review examining amyloid-beta-targeting monoclonal antibodies in Alzheimer's disease ...
In this video interview, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, explains why ...
In today's ACT Brief, we explore practical community engagement strategies that drive representative enrollment, how sponsors ...
In today's ACT Brief, we explore practical steps sponsors can take to prepare for the plausible mechanism framework, how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results